Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jul;58(7):1606-1610.
doi: 10.1111/trf.14634. Epub 2018 Apr 17.

Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant

Keiji Minakawa  1 , Hitoshi Ohto  1 , Hiroyasu Yasuda  1 , Shunichi Saito  1 , Kinuyo Kawabata  1 , Kazuei Ogawa  2 , Kenneth E Nollet  1 , Kazuhiko Ikeda  1
Affiliations
Case Reports

Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant

Keiji Minakawa et al. Transfusion. 2018 Jul.

Abstract

Background: Autoimmune hemolytic anemia (AIHA) is caused by autoantibodies to red blood cells (RBCs), which can be panreactive and/or specific to Rh/other blood group antigens. We report a severe case of AIHA after bone marrow transplantation (BMT) due to autoanti-D triggered by reactivation of Epstein-Barr virus (EBV) infection. A combined strategy of D- RBC transfusion and administration of anti-CD20 monoclonal antibody (MoAb) resolved the hemolysis.

Case report: A 33-year-old male underwent allogeneic BMT from an ABO-identical and HLA-matched unrelated male donor. Five months later, while having mild chronic graft-versus-host disease, he manifested AIHA, with a hemoglobin (Hb) level of 5.1 g/dL on AIHA Day 2 (Posttransplant Day 156) and was refractory to D+ RBCs, with a Hb level of 2.4 g/dL on AIHA Day 6. Anti-D-like autoantibodies (titer 1280, subclass immunoglobulin G1 , monocyte monolayer assay 28.7%) and panreactive (titer 40) were identified. Changing the RBC transfusion strategy to D- increased his Hb level to 6.7 g/dL on Day 10. Administration of anti-CD20 MoAb mitigated EBV-related B-cell proliferation and reduced anti-D autoantibody titer to 320 by Day 16 with normalized Hb concentration after 6 months.

Conclusion: In severe AIHA, when standard treatment and regular RBC transfusions are ineffective, transfusion of RBCs lacking the target antigen(s) of autoantibodies and administration of anti-CD20 MoAb should be considered.

PubMed Disclaimer

References

REFERENCES

    1. Ball LM, Egeler RM. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant 2008; 41:S58-64.
    1. Lee SJ, Vogelsang G. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-33.
    1. Dierickx D, Delannoy A, Saja K, et al. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol 2011;86:278-91.
    1. Issit PD. Chapter 37 “Warm” antibody-induced hemolytic anemia (WAIHA). In: Applied blood group serology. 4th ed. Durham (NC): Montgomery Scientific Publications; 1998. p. 939-93
    1. Ahmed I, Teruya J, Murray-Krezan C, et al. The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant. Pediatr Transplant 2015;19:391-8.

Publication types

MeSH terms

LinkOut - more resources